
Peter Palese, PhD
About Me
http://labs.icahn.mssm.edu/paleselab/
Wikipedia
Visit Dr. Palese's Wikipedia page
Video
Watch a video featuring the Microbiology and Virology Ph.D. Graduate School Program.
Language
English
Position
PROFESSOR & CHAIR EMERITUS | Microbiology, PROFESSOR | Medicine, Infectious Diseases
Research Topics
Antivirals, Apoptosis/Cell Death, Biodefense, Coronavirus, Influenza Virus, Interferon, Interferon Antagonists, Nipah Virus, Paramyxovirus, RNA, SARS Virus, Vaccine Development, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Areas
Disease Mechanisms and Therapeutics (DMT), Microbiology [MIC]
Video
Education
Ph.D., University of Vienna
Awards
2015
Beijerinck Virology Prize
Royal Netherlands Academy of Arts and Sciences
2014
Elected Fellow of the American Academy of Arts and Sciences
2014
Honorary Doctorate
Baylor College of Medicine
2012
Sanofi–Institut Pasteur Award
2012
Election to the Institute of Medicine of the National Academy of Sciences
2010
European Virology Award (EVA)
European Society for Virology
2006
Elected Member
The German Academy of Sciences Leopoldina
2006
Robert Koch Prize
Berlin
2002
Corresponding Member
Austrian Academy of Sciences
2000
Member
National Academy of Sciences
Research
The Palese Laboratory is interested in training students and postdoctoral fellows who will become independent investigators in "molecular" studies of infectious viral diseases.
Publications
Selected Publications
- Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults. Sean T.H. Liu, Irene González-Domínguez, Amparo Martínez-Pérez, Cansu Cimen Bozkus, Oscar Bladh, Tarashon Broomes-Pennicott, Alina Jen, Elizabeth Egan, Edna Leiva-Ortiz, Ashley Abid, Katherina Aguilera, Mikael Åberg, Disha Bhavsar, Temima Yellin, Anass Abbad, Gagandeep Singh, Juan Manuel Carreño, Joshua Adams, Christina Quigley, Mansi Saxena, Marcia Meseck, Ilaria Ceglia, Charlotte Thålin, Daniela Weiskopf, Adolfo García-Sastre, Peter Palese, Weina Sun, Florian Krammer, Judith A. Aberg. Vaccine
- Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines. Mitali Mishra, Eduard Puente-Massaguer, Andrew T. Jones, Jose Martínez-Guevara, Tsoi Ying Lai, Adam Abdeljawad, Kevin Ding, Naiying Zheng, Stylianos Bournazos, Jeffrey V. Ravetch, Florian Krammer, Patrick C. Wilson, Peter Palese, Irene González-Domínguez. Molecular Therapy
- Influenza B mosaic HA mRNA-LNP vaccines are cross-reactive and protective in mice. Irene González-Domínguez, Marta Boza, Adam Abdeljawad, William Shea, Eduard Puente-Massaguer, Mitali Mishra, Nicholas Lemus, Tsoi Ying Lai, Hiromi Muramatsu, Kieu Lam, James Heyes, Jose Luis Martínez-Guevara, Florian Krammer, Peter Palese, Norbert Pardi, Weina Sun. Molecular Therapy Nucleic Acids
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Palese during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- Avimex
- CastleVax
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- CastleVax
Founder/Co-Founder/Partner
- Accurius
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.